Skip to main content
Premium Trial:

Request an Annual Quote

Sequenom Signs Deal with Germany’s Metabion

Premium

Sequenom of San Diego has announced an agreement to sell its MassArray system to Metabion.

 

Terms of the deal were not disclosed.

 

Metabion of Munich will use the system to monitor its oligonucleotide production while providing Sequenom with a source for oligonucleotides, an element in assay development for genotyping technologies.

 

Separately, Sequenom said it had agreed to screen DNA samples linked to type 2 diabetes mellitus provided by the US National Institute of Diabetes and Digestive Kidney Diseases, a division of the USNational Institutes of Health.

 

Sequenom CEO Toni Schuh said the deal would expand the commercial relationship between Sequenom and the National Institutes of Health but he did not offer specifics. Sequenom said it expects current projects from the NIH to generate $500,000 in revenue this year for the company.

 

In addition, Sequenom also recently launched its 384 SpectroChip, which is designed to increase throughput and reduce the costs associated with the analysis of SNPs.

 

Filed under

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.